Combines proprietary, tunable covalent chemistry with a
deep understanding of disease biology to discover and develop transformational medicines that selectively and durably target disease drivers.
Our Team
Who We Are
Dunad Therapeutics is a transatlantic biotech company with teams in Cambridge (UK) and Boston (US). Our scientists and leaders bring decades of experience from top global pharma and biotech organizations — united by a shared mission to bring transformative therapies to patients who have waited too long.
How We Work
We are collaborative, agile, and relentless in our pursuit of discovery. Across borders and time zones, we work as one team — combining creativity, rigor, and passion. Our culture values relationships over hierarchy, teamwork over politics, and the freedom to experiment.
At Dunad, Science is Personal.
Every idea, experiment, and late-night breakthrough is driven by our hope to impact the lives of patients and families living with neurodegenerative diseases such as ALS and PD — the reason we work every day to move new treatments forward.
Leadership Team
Pearl Huang
President & CEO
Stephen Huhn
CMO
Elayne Penebre
SVP R&D
Holly Whittemore
Treasurer & COO
Board of Directors
%20May%202014_tif.png)
Mike Bonney
Chair
Pearl Huang
President & CEO
Elizabeth Roper
Epidarex
Oskar Slotboom
BGV
Varun Gupta
Wellington Partners
Lucy Edwardes Jones
BGF
Our Investors
Portfolio
Our programs are focused on neurodegenerative diseases that need new treatment strategies, and equally important, where the unmet medical need for patients and their families is urgent.
Dunad’s discovery platform enables us to identify precise targets and rapidly generate compounds designed for safety and durable efficacy.
We are motivated by the possibility that each molecule we design could change the course of neurodegenerative disease — turning the tide away from palliative care to that involving proactive treatment.
ALS
(Amyotrophic Lateral Sclerosis)
We are developing a covalent, oral small-molecule therapy aimed at reducing toxic TDP43 protein buildup in the brain and spinal cord — a hallmark of ALS pathology.
Our goal is to extend the period of meaningful independence, mobility and communication for patients.
Parkinson’s Disease
Building on the same foundational chemistry and biology, our Parkinson’s Disease program targets key molecular mechanisms that drive neuronal loss, with the potential to slow disease progression rather than just manage symptoms.
Science
Our goal is simple but ambitious:
To preserve neurological function, preserve movement,
and extend quality of life
for patients & their families.
Pioneering
At Dunad Therapeutics, we’re pioneering a new generation of medicines to treat neurodegenerative diseases such as ALS, FTD and Parkinson’s disease — devastating conditions that currently have few meaningful disease modifying therapeutic options.
Covalent Chemistry
Our discovery platform is built on covalent chemistry, a powerful approach that allows our drug molecules to form a precise, lasting bond with their target, especially in the brain. This durable connection enables our compounds to clear the accumulation of harmful proteins key to many neurodegenerative diseases, while also minimizing unintended effects elsewhere in the body
In simple terms: we can target what matters, and nothing else.
Biological Insight
By combining deep biological insight with our discovery platform, we create selective, long-acting compounds that deliver efficacy at lower, less frequent doses thereby improving tolerability and patient experience compared with standard treatments. We are striving to explore a potential new class of safe, potent oral medicines designed to modulate disease pathways historically considered unreachable.
